<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Scynexis Inc — News on 6ix</title>
    <link>https://6ix.com/company/scynexis-inc</link>
    <description>Latest news and press releases for Scynexis Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 31 Mar 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/scynexis-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835be0678dffbe2df117752.webp</url>
      <title>Scynexis Inc</title>
      <link>https://6ix.com/company/scynexis-inc</link>
    </image>
    <item>
      <title>SCYNEXIS Announces $40.0 Million Private Placement</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-announces-dollar400-million-private-placement</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-announces-dollar400-million-private-placement</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on</description>
    </item>
    <item>
      <title>Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million</title>
      <link>https://6ix.com/company/scynexis-inc/news/poxel-announces-the-sale-of-pxl770-to-scynexis-for-a-total-amount-of-up-to-dollar196-million</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/poxel-announces-the-sale-of-pxl770-to-scynexis-for-a-total-amount-of-up-to-dollar196-million</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>PXL770, a first-in-class direct activator of adenosine monophosphate-activated protein kinase (AMPK), is a clinical-stage drug candidate targeting the</description>
    </item>
    <item>
      <title>SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-completes-transformative-acquisition-of-pxl-770-an-innovative-highly-selective-direct-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-completes-transformative-acquisition-of-pxl-770-an-innovative-highly-selective-direct-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and</description>
    </item>
    <item>
      <title>SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-reports-full-year-2025-financial-results-and-provides-corporate-update-102</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-reports-full-year-2025-financial-results-and-provides-corporate-update-102</guid>
      <pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
      <description>SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the</description>
    </item>
    <item>
      <title>SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-announces-first-participants-dosed-in-a-phase-1-single-ascending-dose-and-multiple-ascending-dose-trial-of-intravenous-scy-247</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-announces-first-participants-dosed-in-a-phase-1-single-ascending-dose-and-multiple-ascending-dose-trial-of-intravenous-scy-247</guid>
      <pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
      <description>Results from IV Phase 1 SAD/MAD Trial Expected in 2026 JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology</description>
    </item>
    <item>
      <title>SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-announces-presentations-highlighting-potent-130000673</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-announces-presentations-highlighting-potent-130000673</guid>
      <pubDate>Wed, 28 Jan 2026 13:00:00 GMT</pubDate>
      <description>This cross-disciplinary meeting highlights the latest discoveries, technologies and translational strategies driving the next generation of antimicrobial solutionsJERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations highlighting data on the Company’s second-generation fungerp drug candidate, SCY-247</description>
    </item>
    <item>
      <title>SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-receives-fda-qualified-infectious-130000043</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-receives-fda-qualified-infectious-130000043</guid>
      <pubDate>Wed, 21 Jan 2026 13:00:00 GMT</pubDate>
      <description>The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal infection JERSEY CITY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration</description>
    </item>
    <item>
      <title>SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-granted-180-day-extension-130000838</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-granted-180-day-extension-130000838</guid>
      <pubDate>Mon, 22 Dec 2025 13:00:00 GMT</pubDate>
      <description>JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). The Company now has until June 15, 2026, to meet the require</description>
    </item>
    <item>
      <title>SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-completes-transfer-brexafemme-drug-120000155</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-completes-transfer-brexafemme-drug-120000155</guid>
      <pubDate>Wed, 19 Nov 2025 12:00:00 GMT</pubDate>
      <description>GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit range JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the</description>
    </item>
    <item>
      <title>Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-announces-federal-funding-collaboration-151500172</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-announces-federal-funding-collaboration-151500172</guid>
      <pubDate>Mon, 17 Nov 2025 15:15:00 GMT</pubDate>
      <description>Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company’s next generation of triterpenoid antifungals (fungerps).Next-generation fungerps, in preclinical stages of development, are targeted to have enhanced pharmacological properties to treat fungal infections where current therapies are limited or not effective, while maintaining broad spectrum of activity against</description>
    </item>
    <item>
      <title>SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-reports-third-quarter-2025-212000096</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-reports-third-quarter-2025-212000096</guid>
      <pubDate>Wed, 05 Nov 2025 21:20:00 GMT</pubDate>
      <description>SCYNEXIS to receive one-time payments totalling $24.8 million from GSK as part of the resolution of the disagreement related to the restart of the Phase 3 MARIO study in invasive candidiasis. Scynexis agreed to GSK’s request to terminate the study.Following the positive SAD/MAD data results announced in September for SCY-247, its second-generation fungerp, the Company expects to initiate a Phase 1 study with the IV formulation and a Phase 2 study for the treatment of invasive candidiasis. The Co</description>
    </item>
    <item>
      <title>SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-gsk-resolve-disagreement-related-120000035</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-gsk-resolve-disagreement-related-120000035</guid>
      <pubDate>Wed, 15 Oct 2025 12:00:00 GMT</pubDate>
      <description>SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasisScynexis will promptly wind-down and terminate the MARIO studyThe payment from GSK, combined with cash in hand and removal of future MARIO expenditures, extends the company’s cash runway to more than two yearsGSK remains committed to the commercialization of BREXAFEMME (ibrexafungerp tablets) JERSEY CITY, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, In</description>
    </item>
    <item>
      <title>SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-announces-positive-results-phase-120000849</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-announces-positive-results-phase-120000849</guid>
      <pubDate>Tue, 30 Sep 2025 12:00:00 GMT</pubDate>
      <description>No safety concerns or dose limiting toxicities observed SCY-247 was able to achieve target exposures at doses lower than our first-generation fungerp Safety, tolerability, and pharmacokinetic profile support the continued clinical development of SCY-247 JERSEY CITY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced positive result</description>
    </item>
    <item>
      <title>SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-announces-multiple-presentations-highlighting-123000196</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-announces-multiple-presentations-highlighting-123000196</guid>
      <pubDate>Thu, 04 Sep 2025 12:30:00 GMT</pubDate>
      <description>Oral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin-resistanceAdditional poster presentations highlight SCY-247’s broad spectrum of antifungal activity, against Candida species, including multidrug- and pandrug-resistant C. auris and Aspergillus speciesCompany anticipates reporting Phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) data for SCY-247 (oral) in Q3 2</description>
    </item>
    <item>
      <title>SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-participate-h-c-wainwright-120000327</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-participate-h-c-wainwright-120000327</guid>
      <pubDate>Mon, 25 Aug 2025 12:00:00 GMT</pubDate>
      <description>JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Scynexis senior leadership team will participate in the H.C. Wainwright 27th Annual Global Conference. Date: Wednesday September 10, 2025Format: In-person presentation and 1x1 meetingsTime: 10:30 a.m.-11:00 a.m. ETLocation: New York, NY If you are interested in</description>
    </item>
    <item>
      <title>SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-reports-second-quarter-2025-203000480</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-reports-second-quarter-2025-203000480</guid>
      <pubDate>Wed, 13 Aug 2025 20:30:00 GMT</pubDate>
      <description>First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary of the new patient dosing; as previously disclosed GSK disputes these milestone payments. SCYNEXIS vigorously disagrees with GSK’s position and is working towards resolving this disagreement; SCYNEXIS is actively working with GSK to transfer the BREXAFEMME New Drug Application (ND</description>
    </item>
    <item>
      <title>SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-resumes-patient-dosing-phase-123000387</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-resumes-patient-dosing-phase-123000387</guid>
      <pubDate>Wed, 28 May 2025 12:30:00 GMT</pubDate>
      <description>First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GSK disputes these milestone payments, and SCYNEXIS vigorously disagrees with their position JERSEY CITY, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prev</description>
    </item>
    <item>
      <title>SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-reports-first-quarter-2025-202000215</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-reports-first-quarter-2025-202000215</guid>
      <pubDate>Thu, 15 May 2025 20:20:00 GMT</pubDate>
      <description>Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme.Hansoh recently received Chinese (NMPA) approval for ibrexafungerp in the treatment of acute VVC. SCYNEXIS will receive a milestone payment from Hansoh upon commercialization as well as royalties of approximately 10% on China sales.Presented positive preclinical data for its second-generation fung</description>
    </item>
    <item>
      <title>SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-present-preclinical-data-second-120000031</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-present-preclinical-data-second-120000031</guid>
      <pubDate>Tue, 08 Apr 2025 12:00:00 GMT</pubDate>
      <description>JERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Vienna, Austria being held from April 11-15, 2025. SCY-247 is being developed to</description>
    </item>
    <item>
      <title>SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/scynexis-inc/news/scynexis-reports-full-2024-financial-210800804</link>
      <guid isPermaLink="true">https://6ix.com/company/scynexis-inc/news/scynexis-reports-full-2024-financial-210800804</guid>
      <pubDate>Wed, 12 Mar 2025 21:08:00 GMT</pubDate>
      <description>The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) congress, April 11-15, 2025 in Vienna, Austria.SCYNEXIS continues to make progress towards the restart of the Phase 3 MARIO study in invasive candidiasis. The Company anticipates the restart, pending the FDA’s</description>
    </item>
  </channel>
</rss>